{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:12:48Z","timestamp":1782537168619,"version":"3.54.5"},"reference-count":57,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2016,5,3]]},"DOI":"10.1586\/17474086.2016.1151351","type":"journal-article","created":{"date-parts":[[2016,2,6]],"date-time":"2016-02-06T17:38:37Z","timestamp":1454780317000},"page":"419-424","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":21,"title":["Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia"],"prefix":"10.1586","volume":"9","author":[{"given":"Yasmin","family":"Rosshandler","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology, the Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Q.","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, the Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"Department of Leukemia, the University of Texas M.D. Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna Jean","family":"Khoury","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, the Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2016,4,21]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199907153410306"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199904293401706"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-358135"},{"key":"CIT0004","unstructured":"Gleevec (Imatinib Mesylate). Administration USFaD. Silver Springs, MD:U.S. Department of Health and Human Services, 2003. [cited 2014 Oct 20]. Available from: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm110502.htm"},{"key":"CIT0005","unstructured":"FDA approves dasatinib (Sprycel) for use in the treatment of adults with chronic phase, accelerated phase, or myeloid or lymphoid blast phase chronic myeloid leukemia. Administration USFaD. Silver Spring, MD:U.S. Department of Health and Human Services, 2006. [cited 2014 Oct 6]. Available at: http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDER\/ucm095630.htm"},{"key":"CIT0006","unstructured":"Nilotinib (Tasigna). Administration USFaD. Silver Spring, MD:U.S. Department of Health and Human Services, 2010. [cited 2014 Oct 6]. Available from: http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDER\/ucm095630.htm"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355594"},{"key":"CIT0009","unstructured":"FDA Approval for Bosutinib. Institute NC. 2013. [cited 2015 May 4]. Available from: http:\/\/www.cancer.gov\/cancertopics\/treatment\/drugs\/fda-bosutinib"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390120"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306494"},{"key":"CIT0012","volume-title":"Administration USFaD","author":"Ponatinib","year":"2012"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21208"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26679"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.7146"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28106"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.38"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-293977"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.012781"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"CIT0021","volume-title":"Network NCC","author":"Chronic Myeloid Leukemia","year":"2014"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600610812"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.12.2.298"},{"issue":"5","key":"CIT0024","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0026-895X(25)10662-7","volume":"11","author":"Huang M-T","year":"1975","journal-title":"Molecular Pharmacology"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1977.tb11256.x"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S41786"},{"issue":"9","key":"CIT0027","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1517\/21678707.2013.828589","volume":"1","author":"Lipton JH","year":"2013","journal-title":"Expert Opinion on Orphan Drugs"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(89)81546-7"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1016\/0167-4781(92)90484-H"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701411466"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-008-0081-8"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.55"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-1963-2"},{"issue":"12","key":"CIT0034","first-page":"1403","volume":"70","author":"Savaraj N","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1046\/j.1359-4117.2003.01066.x"},{"issue":"2","key":"CIT0036","first-page":"139","volume":"21","author":"Lu K","year":"1988","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"CIT0037","first-page":"1085","volume":"68","author":"Legha SS","year":"1984","journal-title":"Cancer Treat Rep"},{"issue":"9","key":"CIT0038","first-page":"801","volume":"67","author":"Neidhart JA","year":"1983","journal-title":"Cancer Treat Rep"},{"issue":"2","key":"CIT0039","first-page":"967","volume":"46","author":"Neidhart JA","year":"1986","journal-title":"Cancer Res"},{"issue":"7","key":"CIT0040","first-page":"693","volume":"67","author":"Coonley CJ","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1007\/BF00179432"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23408"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29240"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.889826"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-326405"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-415307"},{"key":"CIT0047","author":"Akard L","journal-title":"Leukemia & Lymphoma"},{"key":"CIT0048","unstructured":"SYNRIBO Safety Profile: incidence of lab abnormalities. Pharmaceuticals T. Frazer, PA Teva Pharmaceuticals, 2013. [cited 2014 Oct 6]. Available from: http:\/\/www.synribohcp.com\/Adverse_Reactions.aspx"},{"key":"CIT0049","volume-title":"Administration USFaD","author":"Omacetaxine Mepesuccinate","year":"2012"},{"key":"CIT0050","unstructured":"Teva Announces Full FDA Approval of SYNRIBO\u00ae (Omacetaxine Mepesuccinate) for Injection Ltd TPI. Jerusalem:Business Wire, 2014. [Last accessed 2014 Oct 6]. Available from: http:\/\/www.businesswire.com\/news\/home\/20140213005755\/en\/Teva-Announces-Full-FDA-Approval-SYNRIBO%C2%AE-Omacetaxine#.VEFqh1cTUqM"},{"key":"CIT0051","volume-title":"Teva Pharmaceuticals USA I","author":"Medication Guide Synribo (omacetaxine mepesuccinate) for injection, for subcutaneous use","year":"2014"},{"key":"CIT0052","unstructured":"ChemGenex Europe SAS withdraws its marketing authorisation application for Tekinex (omacetaxine mepesuccinate). SAS CE. London, UK: European Medicines Agency, 2011. [cited 2014 Oct 6]. Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2011\/01\/news_detail_001179.jsp&mid=WC0b01ac058004d5c1"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.194"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0230"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70579-5"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-012-0767-5"},{"issue":"8","key":"CIT0057","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","volume":"117","author":"Haouala A","year":"2011","journal-title":"Blood"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/17474086.2016.1151351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T09:49:07Z","timestamp":1748771347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1586\/17474086.2016.1151351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,21]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5,3]]}},"alternative-id":["10.1586\/17474086.2016.1151351"],"URL":"https:\/\/doi.org\/10.1586\/17474086.2016.1151351","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-08-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-04-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}